
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson's positive outlook is supported by its operational sales growth of 11.5% in 4Q25, despite facing a 650 basis points headwind from generic competition for its Stelara product. The company anticipates substantial capital allocation toward its MedTech division following the planned separation of its Orthopedic business, which is expected to enhance revenue growth and bolster its competitive position in key areas such as Cardiovascular, Surgery, and Vision. Additionally, updated revenue projections for 2026 have been raised to $100.42 billion, driven by strong performance in therapeutic areas like Immunology and the potential of new drugs, indicating a robust trajectory for earnings expansion.
Bears say
Johnson & Johnson's financial outlook is concerning due to several fundamental risks impacting its growth potential. The anticipated loss of exclusivity for key pharmaceutical products, combined with underwhelming performance from its pipeline and MedTech division, raises questions about the company's ability to sustain organic revenue growth. Additionally, ongoing litigation issues and the repercussions of potential mergers and acquisitions present added volatility, further complicating the financial landscape for the healthcare giant.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares